Prevalence and risk of new-onset diabetes mellitus after COVID-19: a systematic review and meta-analysis.
COVID – 19
SARS-CoV2 (COVID- 19)
diabetes
incidence
new onset diabetes
systematic review and meta-analysis
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
02
05
2023
accepted:
16
08
2023
medline:
22
9
2023
pubmed:
21
9
2023
entrez:
21
9
2023
Statut:
epublish
Résumé
After the acute phase of SARS-CoV-2 infection, the onset of glycemic impairment and diabetes have been reported. Nevertheless, the exact burden of glycemic impairment and diabetes after COVID-19 has not been clearly described. Electronic search was run in Pubmed (MEDLINE), Web of Science, Scopus, and ClinicalTrial.org for reports published from database inception to September 2022. We included observational studies reporting quantitative data on diabetes prevalence or its onset in subjects with a history of SARS-CoV-2 infection from at least 60 days. Risk of bias was assessed by the JBI's critical appraisal checklist. Random effect model was used to calculate pooled data. The review protocol was registered on PROSPERO (CRD42022310722). Among 1,630 records screened, 20 studies were included in the analysis. The mean or median age of participants ranged from ~ 35 to 64 years, with a percentage of males ranging from 28% to 80%. Only two studies were considered at low risk of bias. The estimate of diabetes prevalence, calculated on a total of 320,948 participants pooled with 38,731 cases, was 16% (95%CI: 11-22%). The estimate of proportion of incident cases of diabetes was 1.6% (95%CI: 0.8-2.7%). Subgroup analysis showed that previous hospitalization increased the prevalence of diabetes and the proportion of incident cases. Diabetes is common in individuals who have experienced SARS-CoV-2 infection, especially if they required hospitalization. This data may be helpful to screen for diabetes and manage its complications in individuals who experienced COVID-19. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022310722, identifier CRD42022310722.
Identifiants
pubmed: 37732118
doi: 10.3389/fendo.2023.1215879
pmc: PMC10507325
doi:
Types de publication
Meta-Analysis
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1215879Informations de copyright
Copyright © 2023 Bellia, Andreadi, D’Ippolito, Scola, Barraco, Meloni, Lauro and Bellia.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMJ. 2021 May 19;373:n1098
pubmed: 34011492
Front Med (Lausanne). 2021 Aug 17;8:663670
pubmed: 34490284
BMC Med. 2021 Sep 27;19(1):249
pubmed: 34565368
Diabetes Care. 2023 Apr 1;46(4):890-897
pubmed: 36826982
Diabetes Res Clin Pract. 2023 Jan;195:110202
pubmed: 36496030
J Clin Endocrinol Metab. 2021 Apr 23;106(5):1472-1481
pubmed: 33513242
JAMIA Open. 2021 Jul 15;4(3):ooab063
pubmed: 34409266
Diabetes Obes Metab. 2021 Mar;23(3):870-874
pubmed: 33245182
Ann Med Surg (Lond). 2022 Aug;80:103995
pubmed: 35721785
J Clin Med. 2021 Jun 30;10(13):
pubmed: 34209085
Diabetes Care. 2022 Dec 1;45(12):2935-2942
pubmed: 36201657
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Pharmacol Rep. 2021 Dec;73(6):1539-1550
pubmed: 34176080
Thorax. 2021 Apr;76(4):396-398
pubmed: 33172844
Metabolism. 2022 Dec;137:155330
pubmed: 36220361
NPJ Digit Med. 2022 Jun 29;5(1):81
pubmed: 35768548
Nat Metab. 2021 Jun;3(6):774-785
pubmed: 34035524
Acta Diabetol. 2021 Nov;58(11):1481-1490
pubmed: 34089096
J Clin Med. 2022 May 30;11(11):
pubmed: 35683480
Inquiry. 2021 Jan-Dec;58:469580211060165
pubmed: 34915771
BMJ Med. 2022 Jun 17;1(1):e000093
pubmed: 36936553
PLoS Med. 2022 Jul 19;19(7):e1004052
pubmed: 35853019
Arch Med Sci. 2021 Mar 18;17(3):818-822
pubmed: 34025853
BMJ. 2021 Mar 31;372:n693
pubmed: 33789877
BMJ Open. 2021 Mar 30;11(3):e048391
pubmed: 33785495
Egypt Liver J. 2021;11(1):74
pubmed: 34777873
Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E736-E741
pubmed: 32228322
Diabetes Res Clin Pract. 2020 Jun;164:108166
pubmed: 32339533
BMC Med. 2022 Nov 15;20(1):444
pubmed: 36380329
Cardiovasc Diabetol. 2020 May 11;19(1):58
pubmed: 32393351
Open Forum Infect Dis. 2022 May 07;9(7):ofac228
pubmed: 35818362
Diabetes Care. 2023 May 1;46(5):938-943
pubmed: 36657086
BMJ. 2015 Mar 16;350:h870
pubmed: 25775931
Immun Inflamm Dis. 2021 Dec;9(4):1563-1572
pubmed: 34414665
Int J Evid Based Healthc. 2015 Sep;13(3):147-53
pubmed: 26317388
Diabetologia. 2022 Jun;65(6):949-954
pubmed: 35292829
MMWR Morb Mortal Wkly Rep. 2022 Jan 14;71(2):59-65
pubmed: 35025851
Front Endocrinol (Lausanne). 2022 Feb 17;13:780663
pubmed: 35250853
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Prim Care Diabetes. 2022 Aug;16(4):591-593
pubmed: 35654679
Front Cardiovasc Med. 2021 Nov 30;8:745758
pubmed: 34917659
Lancet Diabetes Endocrinol. 2021 Nov;9(11):786-798
pubmed: 34619105
Sci Rep. 2022 Nov 23;12(1):20191
pubmed: 36418912
J Epidemiol Community Health. 2013 Nov 1;67(11):974-8
pubmed: 23963506
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Int J Environ Res Public Health. 2022 Oct 14;19(20):
pubmed: 36293857
Clin Transplant. 2022 Apr;36(4):e14572
pubmed: 34967958
Cochrane Database Syst Rev. 2021 Mar 11;3:CD013879
pubmed: 33704775
Lancet Diabetes Endocrinol. 2022 May;10(5):311-321
pubmed: 35325624